INTRODUCTION {#S2}
============

Hematopoiesis is a well-characterized developmental process wherein all adult blood cells are maintained by long-term hematopoietic stem cells (HSC) in the bone marrow (BM) that form mature cells of the lymphoid, myeloid, and erythroid lineages. The lineage-biased progeny of the HSCs rapidly expand, proliferate, and differentiate to respond to the immediate needs of the body until an appropriate systemic response is achieved. HSC reside in a perivascular niche where they have direct contact with quiescence- or proliferation-enforcing signals released from the BM microenvironment ([@R7]; [@R4]; [@R1]). These direct and indirect niche interactions protect HSC quiescence, which is critical for maintaining lifelong hematopoiesis. The nuclear factor κB (NF-κB) family of transcription factors is important for hematopoiesis, including development, differentiation, and homeostasis of different hematopoietic lineages ([@R9]). A major function of NF-κB in hematopoietic cells is to modulate the response to cytokines, pattern-associated molecular patterns, and damage-associated molecular patterns via the tumor necrosis factor receptor (TNFR), interleukin-1 receptor (IL-1R), and toll-like receptors (TLR). NF-κB activation in HSC occurs in response to IL-1R and TLR superfamily stimulation, and in separate studies it is well established that activation of IL-1R and TLRs affects HSC function ([@R32]; [@R11]; [@R39]; [@R18]; [@R36]). For example, administration of low levels of lipopolysaccharide (LPS) in mice, meant to model chronic infection, results in loss of HSC quiescence, reduced HSCs, and myeloid-biased differentiation ([@R11]; [@R50]). Chronic IL1 exposure drives HSC toward precocious myeloid differentiation at the expense of self-renewal ([@R36]). Moreover, tumor necrosis factor alpha (TNF-α) activates the Notch and NF-κB signaling pathways to establish HSC fate, indicating a requirement for inflammatory signaling in HSC generation ([@R10]).

Upon binding to ligands, IL-1R and TLRs sequentially recruit intracellular adaptors, kinases, and effector molecules, which results in nuclear localization and DNA binding of NF-κB homo- or heterodimer transcription factors RelA, c-Rel, RelB, p50/p105, and p52/p100. The current findings support a model in which NF-κB activation occurs downstream of IL-1R/TLRs and contributes to HSC phenotypes during cytokine exposure and infection. However, impaired NF-κB activation as demonstrated by mouse genetic models (i.e., Rela, Relb, Ikbkb, Map3k7/Tak1, Tnfaip3, and Cyld) affects hematopoietic stem/progenitor cell (HSPC) function in the absence of cytokine stimulation or infection ([@R43]; [@R53]; [@R42]; [@R33]; [@R45]; [@R49]), indicating that tonic and/or stochastic NF-κB signaling is required for HSC homeostasis. Surprisingly, deletion of upstream mediators of NF-κB, such as Il1r, Tlr4, Tlr2, MyD88, or Trif results in minimal effects on HSC homeostasis ([@R34]; [@R26]; [@R18]; [@R50]). Thus, despite a crucial role of inflammation- and/or cytokine- independent NF-κB signaling in HSC homeostasis, the tonic signals and upstream mediators of NF-κB in HSC have not been identified.

TNF receptor associated factor 6 (TRAF6), an E3 ubiquitin (Ub) ligase, is a signal transducer for the IL-1R and TLR superfamily, including in response to cytokines, pattern-associated molecular patterns, and damage-associated molecular patterns. In addition, TRAF6 activity is regulated through intracellular homeostatic processes, such as oxidative stress ([@R29]; [@R44]; [@R37]), metabolite changes ([@R24], [@R25]), and DNA damage ([@R19]; [@R51]), which do not require upstream IL-1R/TLR signaling. Independent of the basis for activation, TRAF6 catalyzes the formation of Lys-63-linked polyubiquitin chains on itself and on other protein substrates, such as IκB kinase γ (IKKγ also known as NEMO), leading to a recruitment of a complex containing TAK1, TAK1 binding protein 2 (TAB2), and TAB3 ([@R48]; [@R20]). TAK1 activates the IKK kinase complex (IKKβ and IKKα) leading to NF-κB transcription factor activation ([@R6]; [@R23]). TRAF6 expression is increased in a subset of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients, and its over-expression results in hematopoietic defects in mouse genetic models ([@R41]; [@R12], [@R14]). In addition, deletion of miR-146a and TIFAB, negative regulators of TRAF6 expression and function, are commonly observed in MDS and AML ([@R41]; [@R3]; [@R52], [@R54]; [@R13]; [@R46], [@R47]). Although TRAF6 overexpression is implicated in the MDS HSC defect, the physiological role of TRAF6 in HSC homeostasis and during normal hematopoiesis remains unknown. As such, we reasoned thatTRAF6 might be a critical node in the tonic activation required for maintaining a minimal threshold of NF-κB signaling in HSPC. Here, we report that TRAF6 as an essential regulator of HSC homeostasis by preserving self-renewal and quiescence through basal activation of NF-κB.

RESULTS {#S3}
=======

Deletion of Traf6 in Hematopoietic Cells Leads to Premature Lethality and Hematologic Defects {#S4}
---------------------------------------------------------------------------------------------

To define the role of TRAF6 in normal hematopoiesis, we first determined the expression of TRAF6 mRNA and protein in mouse BM populations by qRT-PCR and immunoblotting, respectively. *Traf6* mRNA was broadly expressed in all mouse hematopoietic lineages examined ([Figure 1A](#F1){ref-type="fig"}). *Traf6* was \~2-fold higher in LT-HSC (lineage^−^cKit^+^Sca1^+^CD34^−^CD135^−^), common lymphoid progenitors (lineage^−^cKit^low^Sca1^low^CD127^+^), and myeloid progenitors (lineage^−^cKit^+^Sca1^+^CD34^+^CD16/32^−^ and lineage^−^cKit^+^Sca1^−^CD34^−^CD16/32^−^) as compared to CD11b^+^ myeloid cells ([Figure 1A](#F1){ref-type="fig"}). Traf6 protein expression was also \~2.0-fold higher in lineage^−^cKit^+^Sca1^+^ (LSK) and lineage^−^cKit^+^ (LK) cells as compared to CD11b^+^ myeloid cells ([Figure 1B](#F1){ref-type="fig"}). The expression of TRAF6 in HSC led us to speculate that TRAF6 might have a role in HSC function and/or homeostasis. We disrupted the Traf6 gene in the hematopoietic lineage by crossing *Traf6*-floxed mice with VavCre^+^ transgenic mice, in which a transgene encoding Cre recombinase is expressed specifically in all hematopoietic cells including LT-HSC (*Traf6*^−/−^VavCre^+^) ([Figure S1A](#SD1){ref-type="supplementary-material"}) ([@R35]). Traf6 loss was confirmed in *Traf6*^−/−^VavCre^+^ mice by PCR of genomic DNA, by qRT-PCR to detect *Traf6* mRNA, and by immunoblotting to detect loss of Traf6 protein expression ([Figures 1C](#F1){ref-type="fig"}, [S1A, and S1B](#SD1){ref-type="supplementary-material"}). Deletion of Traf6 was restricted to hematopoietic cells, as Traf6 mRNA and protein were detectable in non-hematopoietic cells isolated from the liver, brain, and intestine of *Traf6*^−/−^VavCre^+^ and control mice (VavCre^+^) ([Figures S1B and S1C](#SD1){ref-type="supplementary-material"}). Although *Traf6*^−/−^VavCre^+^ were born at the expected Mendelian frequencies ([Figure S2A](#SD1){ref-type="supplementary-material"}), the deletion of Traf6 in hematopoietic cells resulted in premature lethality with a median survival of 9.5 weeks (p \< 0.0001) ([Figure S2B](#SD1){ref-type="supplementary-material"}). A histological assessment of major organs revealed that all intestinal tissues from *Traf6*^−/−^VavCre^+^ mice appeared normal and similar to control mice ([Figures S3A and S3B](#SD1){ref-type="supplementary-material"}). However, the lungs and livers from *Traf6*^−/−^VavCre^+^ mice exhibited infiltration of immune cells, which may contribute to the early mortality and morbidity of the mice ([Figures S3C and S3D](#SD1){ref-type="supplementary-material"}). Deletion of Traf6 in hematopoietic cells resulted in significant effects on blood formation. Peripheral blood (PB) counts of 5- to 10-week-old *Traf6*^−/−^VavCre^+^ mice revealed neutrophilia (p = 0.028), lymphopenia (p \< 0.0001), and anemia (p = 0.0037) ([Table S1](#SD1){ref-type="supplementary-material"}). The proportion of CD11b^+^ myeloid cells (p \< 0.0001) was significantly increased while the proportion of CD3^+^ T cells (p = 0.2) and B220^+^ B cells (p \< 0.0001) was reduced in the PB of *Traf6*^−/−^VavCre^+^ mice as compared to control VavCre^+^ mice ([Figures S4A and S4B](#SD1){ref-type="supplementary-material"}). The BM cellularity of Traf6-deleted mice was reduced by more than 50% between 5--10 weeks of age as compared to control mice, which is due to the reduced body size of *Traf6*^−/−^VavCre^+^ mice ([Figure S4C](#SD1){ref-type="supplementary-material"}). The proportion of myeloid cells (p = 0.2) was moderately increased, while the frequency of B cells was reduced in the BM of *Traf6*^−/−^VavCre^+^ mice as determined by flow cytometry (p \< 0.0001) ([Figure S4D](#SD1){ref-type="supplementary-material"}).

To determine whether the hematologic defects associated with deletion of Traf6 in hematopoietic cells are cell-intrinsic and transplantable, BM cells from *Traf6*^−/−^VavCre^+^ and control VavCre^+^ mice were transplanted into lethally irradiated congenic recipient mice ([Figure 1D](#F1){ref-type="fig"}). Recipient mice reconstituted with *Traf6*^−/−^VavCre^+^ BM cells succumbed to hematologic defects with a median survival time of 32 weeks (p = 0.0061) ([Figure S4E](#SD1){ref-type="supplementary-material"}), indicating that Traf6-deficient hematopoietic defects are transplantable. Consistent with non-transplanted *Traf6*^−/−^VavCre^+^ mice, recipient mice reconstituted with *Traf6*^−/−^VavCre^+^ BM cells developed leukopenia (p \< 0.0001), lymphopenia (p \< 0.0001), and neutrophilia (p = 0.0016) ([Table S2](#SD1){ref-type="supplementary-material"}). The proportion of CD11b^+^ myeloid cells (p \< 0.0001) were increased while the frequencies of B220^+^ B lymphocytes (p \< 0.0001) and CD3^+^ T lymphocytes (p \< 0.0001) were reduced in the PB of recipient mice reconstituted with *Traf6*^−/−^VavCre^+^ BM cells as compared to recipient mice reconstituted with control BM cells ([Figure S4F](#SD1){ref-type="supplementary-material"}). Unlike non-transplanted *Traf6*^−/−^VavCre^+^ mice, recipient mice reconstituted with *Traf6*^−/−^VavCre^+^ BM cells did not develop a hypocellular BM as compared to recipient mice reconstituted with control (VavCre^+^) BM cells (data not shown). Nevertheless, the proportion of myeloid cells (p \< 0.05) was increased, while the frequencies of B220^+^ B lymphocytes (p \< 0.05) were reduced in the BM of recipient mice reconstituted with *Traf6*^−/−^VavCre^+^ BM cells as compared to recipient mice reconstituted with control BM cells ([Figure S4G](#SD1){ref-type="supplementary-material"}).

Deletion of Traf6 Leads to Loss of HSPC {#S5}
---------------------------------------

To determine whether Traf6 is required for HSPC homeostasis, BM cells were examined in *Traf6*^−/−^VavCre^+^ and control VavCre^+^ mice. The proportions of LSK and LK were comparable in the BM of *Traf6*^−/−^VavCre^+^ or VavCre^+^ mice ([Figure S5](#SD1){ref-type="supplementary-material"}). In contrast, *Traf6*^−/−^VavCre^+^ mice exhibited reduced proportions of CD150^+^LSK in the BM as compared to VavCre^+^ mice ([Figure S5](#SD1){ref-type="supplementary-material"}). To examine HSPC function following hematopoietic reconstitution, BM cells from *Traf6*^−/−^VavCre^+^ and control VavCre^+^ mice were transplanted into lethally irradiated congenic recipient mice ([Figure 1D](#F1){ref-type="fig"}). Four months after transplantation, HSPC proportions were examined by flow cytometry ([Figure 1E](#F1){ref-type="fig"}). The proportions of LSK and LK in the BM were comparable in recipient mice reconstituted with *Traf6*^−/−^VavCre^+^ or VavCre^+^ BM cells ([Figure 1F](#F1){ref-type="fig"}). However, mice reconstituted with *Traf6*^−/−^VavCre^+^ BM cells had significantly reduced proportions of CD150^+^LSK, common myeloid progenitor (CMP), and megakaryocyte-erythroid progenitor (MEP) cells in the BM ([Figures 1G and 1H](#F1){ref-type="fig"}). The absolute numbers of HSPC on the basis of their frequencies and BM cellularity was also calculated. We observed fewer numbers of CD150^+^LSK, CMP, and MEP cells in *Traf6*^−/−^VavCre^+^ BM ([Figures 1G and 1H](#F1){ref-type="fig"}). Examination of HSPC proportions and absolute numbers in spleens revealed that LSK and CD150^+^LSK were moderately increased in the spleen of mice reconstituted with *Traf6*^−/−^VavCre^+^ BM as compared to control BM cells ([Figures S6A and S6B](#SD1){ref-type="supplementary-material"}). Granulocyte-monocyte progenitor (GMP) proportions and total numbers were moderately increased in the BM and spleen of mice reconstituted with *Traf6*^−/−^VavCre^+^ BM cells ([Figures 1H](#F1){ref-type="fig"} and [S6C](#SD1){ref-type="supplementary-material"}). Common lymphoid progenitor (CLP) proportions and total numbers were decreased in mice reconstituted with *Traf6*^−/−^VavCre^+^ BM cells as compared to littermate controls, which may explain the lymphopenia in *Traf6*-deficient mice ([Figure 1I](#F1){ref-type="fig"}). Collectively, Traf6 deficiency predominantly results in reduced HSC and lymphoid progenitors.

*Traf6* Deletion Diminishes the Self-Renewal of HSC {#S6}
---------------------------------------------------

To evaluate the self-renewal potential of *Traf6*-deficient HSC, we performed competitive BM transplantation assays. Equal numbers of BM cells from *Traf6*^−/−^VavCre^+^ or VavCre^+^ mice (CD45.2^+^) were mixed with wild-type competitor cells (CD45.1^+^), transplanted into lethally irradiated congenic recipient mice, and then donor-derived (CD45.2^+^) hematopoietic reconstitution was determined by fluorescence-activated cell sorting (FACS) ([Figure 2A](#F2){ref-type="fig"}). The hematopoietic contribution of *Traf6*^−/−^VavCre^+^ BM cells to peripheral blood chimerism was significantly reduced (from \~50% to \<5%) compared with VavCre^+^ donor BM cells ([Figures 2B and 2C](#F2){ref-type="fig"}). The reduced PB chimerism of *Traf6*^−/−^VavCre^+^ BM cells was a result of diminished numbers of myeloid (CD11b^+^) and lymphoid (CD3^+^ and B220^+^) cells as compared to mice reconstituted with control (VavCre^+^) BM cells, which persisted for \>4 months post BM transplantations ([Figure 2D](#F2){ref-type="fig"}). BM chimerism of LT-HSC (LSKCD150^+^CD48^−^; p = 0.003), HPC (LSK, p = 0.002; LK, p = 0.02; and Lin^−^, p = 0.01), and mononuclear cells was significantly reduced for *Traf6*^−/−^VavCre^+^ donor BM cells as compared to control donor BM cells 4 months post competitive transplantations ([Figure 2E](#F2){ref-type="fig"}). These findings suggest that Traf6-deficient HSC are functionally defective and incapable of long-term reconstitution.

Hematopoietic reconstitution of Traf6-deficient BM cells was significantly reduced within 4 weeks of BM transplantation, which prompted us to determine whether Traf6-deficient HSPC are defective at homing and/or migration to the BM. BM cells from *Traf6*^−/−^VavCre^+^ and VavCre^+^ mice were plated in methylcellulose to assess progenitor colony formation ("before homing"), or transplanted into lethally irradiated recipients. Sixteen hours post transplantation, BM cells were recovered from the recipients and plated in methylcellulose to determine progenitor colony formation ("after homing") ([Figure S7A](#SD1){ref-type="supplementary-material"}). Homing of HSC to the BM was calculated based on the frequency of colony forming units recovered after BM transplantation relative to the colony forming units before BM transplantation. The hematopoietic defect associated with Traf6-deficient HSPC is not likely due to a homing deficiency as the homing of *Traf6*^−/−^VavCre^+^ HSPC to the BM was comparable to control (VavCre^+^) HSPC ([Figure S7B](#SD1){ref-type="supplementary-material"}). In parallel, migration of *Traf6*^−/−^VavCre^+^ and VavCre^+^ LSK and LK cells across a transwell toward a CXCL12 gradient was determined. As compared to VavCre^+^, *Traf6*^−/−^VavCre^+^ LSK or LK did not show a significant defect in migration ([Figure S7C](#SD1){ref-type="supplementary-material"}), thus suggesting that alterations in homing and/or migration to the BM do not account for the defects associated with Traf6-deficient HSPC.

To determine whether the observed HSC phenotype in Traf6-deficient mice is cell intrinsic in older mice and unrelated to the consequences of BM transplantation, we generated conditional Traf6-deficient mice by crossing *Traf6*^fl/fl^ with interferon-inducible Mx1Cre transgenic mice (*Traf6*^f/f^Mx1Cre^+^). BM cells from *Traf6*^f/f^Mx1Cre^+^ or Mx1Cre^+^ control mice (CD45.2^+^) together with the same number of wild-type CD45.1 competitor BM cells were transplanted into lethally irradiated CD45.1 recipient mice. One month post transplantation and prior to administration of polyinosinic-polycytidylic acid (pIpC) to induce Traf6 deletion, CD45.2^+^ chimerism was comparable in recipients with BM cells from *Traf6*^−/−^Mx1Cre^+^ mice and Mx1Cre^+^ mice. Subsequently, the transplanted mice were treated with pIpC injections to induce Traf6 deletion and monitored for 5 months ([Figure 3A](#F3){ref-type="fig"}). Five months after deletion of Traf6, CD45.2^+^ cells were significantly reduced in the peripheral blood and BM of recipient mice ([Figures 3B and 3C](#F3){ref-type="fig"}), which is consistent with phenotype observed in *Traf6*^−/−^VavCre^+^ mice. Reduced chimerism of *Traf6*^−/−^Mx1Cre^+^ CD45.2^+^ cells in the PB was observed in both myeloid (CD11b^+^) and lymphoid (CD3^+^ and B220^+^) populations ([Figure 3B](#F3){ref-type="fig"}). Moreover, Traf6 deletion resulted in a significant reduction of phenotypically defined LT-HSC (LSKCD150^+^CD48^−^; p = 0.004) and HSPC (LSK, p = 0.002; LK, p = 0.03; and Lin^−^, p = 0.03) ([Figure 3C](#F3){ref-type="fig"}). To define the function of LT-HSC, we examined hematopoietic contribution of *Traf6*^−/−^Mx1Cre^+^ mice and Mx1Cre^+^ LT-HSC following serial BM transplantations in lethally irradiated CD45.1 recipient mice. The hematopoietic contribution of *Traf6*^−/−^Mx1Cre^+^ HSC to long-term PB chimerism in secondary recipient mice was significantly reduced compared to wild-type donor Mx1Cre^+^ HSPC (p \< 0.05) ([Figure 3D](#F3){ref-type="fig"}). In addition, Traf6 deletion resulted in a reduction of LT-HSC (LSKCD150^+^; p = 0.07) and HSPC (LSK, p = 0.016) in secondary recipient mice, indicating that Traf6 is required for long-term HSC function ([Figure 3E](#F3){ref-type="fig"}). Collectively, the data above suggests that Traf6 expression is important for HSC homeostasis, self-renewal, and progenitor differentiation.

Traf6 Is Required for Maintaining HSC Quiescence {#S7}
------------------------------------------------

To identify the reason for the loss of HSC in Traf6-deficient mice, we examined cell survival and quiescence of HSPC, mechanisms responsible for maintaining normal HSC homeostasis. Increased cell death, as determined by TUNEL staining, was not significantly different between HSPC (Lin^−^ cells) isolated from the BM of VavCre^+^ and *Traf6*^−/−^VavCre^+^ mice ([Figure 4A](#F4){ref-type="fig"}). In contrast, differentiated HSPC (Lin^+^ cells) exhibited \~2-fold increase in TUNEL+ cells isolated from *Traf6*^−/−^VavCre^+^ mice as compared to Lin^+^ cells from VavCre^+^ ([Figure 4A](#F4){ref-type="fig"}). The majority of LT-HSCs are in a quiescent cell-cycle state, which is necessary to preserve their long-term function and self-renewal capacity. Therefore, we next examined the cell-cycle status of *Traf6*^−/−^VavCre^+^ and VavCre^+^ HSPC by Ki-67 and Hoechst 33342 staining. As expected, control (VavCre^+^) CD150^+^LSK are primarily in G~0~ (67%) and rarely in G~1~ or S/G~2~/M of the cell cycle, an indication of cellular quiescence ([Figures 4B and 4C](#F4){ref-type="fig"}). In contrast, the frequencies of CD150^+^LSK fraction in the G~0~ phase were reduced in *Traf6*^−/−^VavCre^+^ mice (43%), consistent with reduced cellular quiescence and increased proliferation ([Figures 4B and 4C](#F4){ref-type="fig"}). Increased cell proliferation of Traf6-deficient LSK and LK was also observed ([Figure 4C](#F4){ref-type="fig"}). BrdU incorporation was modestly increased in LSK cells (6.7% versus 10.7%; p = 0.3), but not in CD150^+^LSK, from *Traf6*^−/−^VavCre^+^ mice as compared to control VavCre^+^ mice ([Figure 4D](#F4){ref-type="fig"}). These data indicate that Traf6 deficiency results in loss of cell quiescence and premature exhaustion of the HSC pool, and increased proliferation of HSPC.

Altered Gene Expression in Traf6-Deficient HSPC {#S8}
-----------------------------------------------

To gain mechanistic insight into the consequences of Traf6 deletion on impaired HSPC function, we performed RNA sequencing (RNA-seq) using LSK isolated from recipient mice 2 months post BM transplantation with *Traf6*^−/−^VavCre^+^ or VavCre^+^ BM cells (n = 4 per group). 776 genes were differentially expressed in *Traf6*^−/−^VavCre^+^ LSK compared with control (VavCre^+^) LSK cells (\>1.5-fold; p \< 0.05) ([Figure 5A](#F5){ref-type="fig"}; [Table S3](#SD2){ref-type="supplementary-material"}). Gene set enrichment analysis (GSEA) revealed that *Traf6*^−/−^VavCre^+^ LSK cells had reduced expression of genes that are normally expressed by LT-HSC cells (p = 0; normalized enrichment score \[NES\] = 1.58), and showed increased expression of gene profiles associated with hematopoietic progenitor cells (p = 0; NES = −1.55) ([Figures 5B--5D](#F5){ref-type="fig"}). Loss of genes that are normally expressed by LT-HSC cells and acquisition of genes associated with hematopoietic progenitors is consistent with reduced quiescence and increased proliferation of *Traf6*^−/−^VavCre^+^ HSC. We did not observe a gene signature associated with apoptosis in Traf6-deficient LSK, suggesting apoptosis is not the main cause resulting in diminished HSPC numbers and function. Pathway analysis networks using the Reactome Database revealed changes in adaptive immune signaling, innate immune signaling, and NF-κB signaling ([Figure 5E](#F5){ref-type="fig"}). A loss of gene regulatory networks associated with immune signaling is particularly intriguing as it suggests that tonic signaling via TRAF6 in HSPC occurs in the absence of acute infection and correlates with diminished LT-HSC gene expression signature. Consistent with these analyses, *Traf6*^−/−^VavCre^+^ LSK cells had reduced expression of NF-κB target genes that are characteristically activated by inflammatory cytokines, such as TNF-α, as determined by GSEA (p = 0.0; NES = 1.72) and by qRT-PCR ([Figures 6A and 6B](#F6){ref-type="fig"}).

TRAF6 has been previously implicated in controlling alternative RNA splicing in HSPC through ubiquitination of RNA binding proteins ([@R14]). To determine whether loss of TRAF6 affects RNA isoform expression and alternative splicing, we next performed paired-end RNA-seq from poly(A)-selected *Traf6*^−/−^VavCre^+^ and VavCre^+^ LSK RNA and applied a percent spliced-in (PSI) algorithm using aligned exon-exon and exon-intron junction reads (MultiPath-PSI in the software AltAnalyze). Using a PSI difference of \>10% between matched replicates, we identified 223 alternative splicing events unique to *Traf6*^−/−^VavCre^+^ LSK as compared to VavCre^+^ LSK, with an enrichment of genes essential for hematopoietic cell function ([Figure S8A](#SD1){ref-type="supplementary-material"}; [Table S4](#SD3){ref-type="supplementary-material"}). As one explanation for diminished NF-κB activation in TRAF6-deficient HSPC, we found that *Traf6*^−/−^VavCre^+^ LSK exhibit alternative splicing of *Nfkb1*, which encodes p105/p50, a member of the NF-κB transcription factor family. *Traf6*^−/−^VavCre^+^ LSK preferentially retain exon 25 in *Nfkb1*, which has previously been shown to result in expression of the cytoplasmic version of Nfkb1 (p105) and diminished NF-κB nuclear translocation and DNA-binding ([@R16]). In contrast, control LSK cells (VavCre^+^) express nuclear versions of Nfkb1 (p50, p63, and p84), as evident by exclusion of exon 25 ([Figures S8B and S8C](#SD1){ref-type="supplementary-material"}). To assess NF-κB pathway activation, we examined total and phosphorylated IKKβ, IKKα, and RelA/p65 in *Traf6*^−/−^VavCre^+^ and control Lin^−^ BM cells by immunoblotting, and RelA/p65 in *Traf6*^−/−^VavCre^+^ and control LSK cells by immunofluorescence. Phosphorylated IKKβ and p65 were reduced in *Traf6*^−/−^VavCre^+^ Lin^−^ BM cells as compared with control (VavCre^+^) Lin^−^ BM cells ([Figure 6C](#F6){ref-type="fig"}). Moreover, nuclear and total p65 was reduced in *Traf6*^−/−^VavCre^+^ LSK cells by 45% as compared with control (VavCre^+^) LSK cells ([Figures 6D](#F6){ref-type="fig"} and [S9](#SD1){ref-type="supplementary-material"}). Collectively, these findings indicate that TRAF6 is required for maintaining a minimal threshold level of IKK/NF-κB signaling in HSPC.

IKKβ Deficiency Leads to Loss of HSPC and Impaired Hematopoietic Reconstitution {#S9}
-------------------------------------------------------------------------------

HSPC are exquisitely sensitive to fluctuations in IKK/NF-κB expression, therefore re-establishing the optimal threshold of IKKβ activity in Traf6-deficient HSPC cells was not feasible (data not shown). As an alternative approach to investigate the relevance of diminished IKK/NF-κB signaling in HSPC, we determined whether IKKβ (*Ikbkb*) loss is sufficient to recapitulate the hematopoietic defects observed in Traf6-deficient BM. IKKβ was selected as it is immediately downstream of TRAF6 signaling and is responsible for initiating NF-κB nuclear translocation and transcriptional activation. We generated conditional IKKβ-deficient mice by crossing *Ikbkb-*floxed mice with VavCre^+^ transgenic mice (*IKK*^−/−^VavCre^+^). Equal numbers of whole BM cells from *IKK*^−/−^VavCre^+^ or *IKK*^f/f^VavCre^−^ mice (CD45.2^+^) were mixed with wild-type competitor cells (CD45.1^+^), transplanted into lethally irradiated congenic recipient mice ([Figure 6E](#F6){ref-type="fig"}), and then donor-derived (CD45.2^+^) hematopoietic reconstitution in the BM, peripheral blood, and spleen was determined by FACS. Peripheral blood chimerism of *IKK*^−/−^VavCre^+^ BM cells was significantly diminished within 4 weeks post transplantation and remained \<1% after 16 weeks ([Figure 6F](#F6){ref-type="fig"}). The hematopoietic contribution of *IKK*^−/−^VavCre^+^ BM cells to BM and spleen chimerism was also significantly reduced (from \~50% to \<5%) compared with VavCre^+^ donor BM cells ([Figures 6G and 6H](#F6){ref-type="fig"}). Moreover, chimerism of LSK and LK from *IKK*^−/−^VavCre^+^ BM cells was dramatically diminished ([Figures 6I and 6J](#F6){ref-type="fig"}). These findings suggest that Traf6-deficient HSC are functionally defective and incapable of long-term reconstitution due in part to diminished basal activation of IKKβ and NF-κB ([Figure 7](#F7){ref-type="fig"}).

DISCUSSION {#S10}
==========

Our study demonstrates that TRAF6 is essential for HSC homeostasis. Hematopoietic-specific deletion of *Traf6* resulted in reduced immune- and NF-κB-related gene signatures and impaired HSC function. Therefore, signaling via TRAF6 occurs in HSPC and correlates with diminished HSC function in the absence of inflammation and/or infection. We also established that loss of NF-κB signaling contributes to the major hematopoietic defects observed in Traf6-deficient HSPC; that is, IKKβ-deficient HSPC resulted in severely impaired HSC self-renewal and fitness. Our observations suggest that TRAF6 is an essential regulator of HSC homeostasis by maintaining a minimal threshold level of NF-κB signaling ([Figure 7](#F7){ref-type="fig"}).

Although we describe a functional requirement of TRAF6 in normal hematopoiesis, a role TRAF6 in HSC function was inferred from a large-scale mRNA expression and gene mapping analysis performed to identify genes and loci that control HSC function in a panel of densely genotyped recombinant inbred mouse strains. Mapping of quantitative trait loci identified Traf6 as a *trans*-acting control loci associated with variations in attributes of HSC populations ([@R5]). Our findings that TRAF6 dosage and activity are important for HSC homeostasis are congruent with its role in hematologic malignancies, such as MDS. Chronic TLR activation compromises HSC function and induces myeloid-biased differentiation, yet if not resolved, results in cytopenias, myeloid dysplasia, and BM failure. Canonical NF-κB signaling is not sufficient to induce MDS in mice ([@R2]; [@R38]), indicating that other pathways downstream of TRAF6 contribute to the initiation of MDS. Utilizing a hematopoietic-specific TRAF6 overexpression mouse model, we recently reported a mechanism by which TRAF6 mediates ubiquitination of hnRNPA1, alters RNA exon usage and contributes to MDS-associated HSPC defects in part by activating Cdc42 ([@R14]). These findings along with our RNA splicing analysis in TRAF6-deficient HSPC ([Figure S8](#SD1){ref-type="supplementary-material"}) reinforce the contribution of TRAF6 to the control of hematopoietic-requisite RNA isoforms. Therefore, TRAF6 may elicit distinct and overlapping regulatory functions during normal and malignant hematopoiesis.

Through genetic loss-of-function models, TRAF6 has been linked to the function of various immune effector cells. Mice deficient in Traf6 succumb to perinatal and postnatal lethality and develop osteopetrosis due to impaired osteoclast function and defects in bone remodeling ([@R27]). Additional immune-related functions were revealed after deletion of TRAF6 in the myeloid and lymphoid compartments ([@R21]; [@R22]; [@R17]; [@R31]). We suspect that some of the hematologic phenotypes observed in our hematopoietic-specific Traf6-deficient mice may arise from defects in myeloid and/or lymphoid populations. However, our competitive BM transplantation data indicate that impaired HSPC numbers and function in hematopoietic-specific Traf6-deficient mice is primarily due to loss of TRAF6 in HSPC and not secondary from loss of TRAF6 in immune effector cells.

As we and others have shown, deletion of NF-κB/p65 or its kinase (IKKβ) results in aberrant HSC function ([@R42]; [@R49]). Interestingly, deletion of upstream mediators of NF-κB, such as IL-1R, TLRs, or receptor adaptors does not result in diminished HSC homeostasis and/or function ([@R34]; [@R26]; [@R18]; [@R50]), suggesting that an intermediate signaling node, such as TRAF6, is required for mediating a minimal threshold level of NF-κB activation in HSC. Thus, TRAF6 is important not only for ligand-mediated responses in immune effector cells, but also for maintaining basal NF-κB signaling in HSPC. Tonic signaling is an established survival and selection mechanism for immune cells, including B- and T-lymphocytes. Low and intermediate affinity interactions result in tonic T cell receptor signaling that is required to keep T cells responsive to antigen ([@R15]). In addition, ligand-independent tonic signaling in B cells is essential for their survival and function. BCR signaling occurs independently of antigen, and, furthermore, these non-induced or "tonic" signals are linked to specific cellular processes operating at multiple stages of B cell development ([@R30]). For example, NF-κB pathways mediate the survival of follicular B cells through tonic BCR signals that generate the NF-κB subunit p100 ([@R40]).

Although our studies suggest that tonic NF-κB signaling via TRAF6 is important for the maintenance of HSC, the precise mechanism of TRAF6 activation during HSPC homeostasis remains unknown. TRAF6 activity can be regulated through intracellular homeostatic processes, such as oxidative stress ([@R29]; [@R44]; [@R37]), metabolite changes ([@R24], [@R25]), and DNA damage ([@R19]; [@R51]), which do not require upstream IL-1R or TLR signaling. Therefore, it is possible that TRAF6 responds to oxidative, metabolic, and genotoxic mechanisms in HSC via non-receptor signaling intermediates. Alternatively, stochastic auto-activation of TRAF6 E3 ubiquitin ligase activity might stimulate downstream signaling; in this case, an upstream signal is not obligatory. In summary, we show that TRAF6 dosage is important for HSC function, and that TRAF6 maintains a minimal threshold level of NF-κB signaling necessary for hematopoietic stem cell homeostasis ([@R28]).

EXPERIMENTAL PROCEDURES {#S11}
=======================

Mice {#S12}
----

All mice were bred, housed, and handled in the Association for Assessment and Accreditation of Laboratory Animal Care-accredited animal facility of Cincinnati Children's Hospital Medical Center (CCHMC) or Memorial Sloan Kettering Cancer Center (MSKCC). Animal care was in strict compliance with the institutional guidelines established by CCHMC and MSKCC, the Guide for the Care and Use of Animals, and the Association for Assessment and Accreditation of Laboratory Animal Care International. *TRAF6*^fl/fl^ mice (C57BL/6) were a kind gift from Dr. Yongwon Choi (University of Pennsylvania) ([@R17]). *Traf6^fl/fl^* mice were crossed with Mx1Cre (Jackson Laboratory, 003556) and VavCre mice (Jackson Laboratory, 008610) for inducible or conditional deletion of TRAF6 (*Traf6*^fl/fl^;Mx1Cre) and (*Traf6*^fl/fl^; VavCre), respectively. To delete TRAF6, Cre transgene expression in *Traf6*^fl/fl^;Mx1Cre mice was induced by pIpC. *IKK*β^fl/fl^ mice were previously described and a kind gift from Dr. Albert Baldwin (University of North Carolina) ([@R28]). To delete IKKβ in hematopoietic cells, *IKK*β*^fl/fl^* mice were crossed with VavCre mice. BM cells were obtained by crushing the femur, tibia, and pelvic bone, and maintained in RPMI1640 with 10% fetal bovine serum.

Alternative Splicing Analysis {#S13}
-----------------------------

To identify differentially spliced exons and introns, we performed RNA-seq from total RNA (Illumina HiSeq 2500), at an average depth of \~37 million paired-end 100 nt reads using the TruSeq RNA Library Prep Kit (Illumina) by the University of Cincinnati Genomics Sequencing Core. These subsequent FASTA files were supplied as input for genome alignment (mm10) with the software STAR to produce BAM files with read-strand predictions resulting in \~72% aligned reads on average. Alternative splicing detection and quantification was performed in the software AltAnalyze version 2.1.1 ([@R8]), using the recently developed MultiPath-PSI algorithm that applies an unbiased local splicing variation-based percent splicing analysis to all overlapping exon-exon and exon-intron aligned reads (paired-end data required for intron-retention analysis) (<http://altanalyze.readthedocs.io/en/latest/Algorithms/#multipath-psi-splicing-algorithm>). The default delta PSI cutoff of 0.1 (10% inclusion difference) was applied to comparison of paired *Traf6*^−/−^VavCre^+^ and Vav-Cre^+^ LSK and consistently differential splicing events selected between the two replicate experiments. Gene set enrichment analysis of the consistently detected splicing events was performed using the software ToppFun.

Statistical Analysis {#S14}
--------------------

RNA-seq was performed using n = 4 mice per group. Blood count analysis and organ weights were recorded as indicated in the figure legends. For secondary or competitive transplantation experiments, two donor mice were used for all recipients. Survival experiments were performed as indicated in the figure legends. The number of animals, cells, and experimental replicates can be found in the figure legends. Unless otherwise specified, results are depicted as the mean ± SEM. Statistical analyses were performed using Student's t test (unpaired, two-tailed). For Kaplan-Meier analysis, Mantel-Cox test was used. Data were analyzed and plotted using GraphPad Prism 6 software. For correlative analyses, Spearman rank test was used.
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![Deletion of Traf6 in Hematopoietic Cells Leads to Reduced HSPC\
(A) *Traf6* mRNA expression by qRT-PCR in the indicated mouse BM hematopoietic stem and progenitor cell subpopulations (n = 5 per group).\
(B) Traf6 protein expression by immunoblotting in the indicated mouse BM cells.\
(C) Traf6 protein expression by immunoblotting in lineage^−^ BM (Lin^−^ BM) cells from VavCre^+^ and *Traf6*^−/−^VavCre^+^ mice (pooled from 2 mice).\
(D) Outline of non-competitive BM transplantations using VavCre^+^ or *Traf6*^−/−^VavCre^+^ mice.\
(E) Representative flow cytometric analysis of HSPC subpopulations within the BM of recipient mice transplanted with the VavCre^+^ and *Traf6*^−/−^VavCre^+^ BM cells.\
(F--I) Frequency (left) and number (right) of LSK or LK (F), CD150^+^LSK or CD150^−^LSK (G), CMP, GMP, or MEP (H), and CLP (I) from the BM of recipient mice transplanted with VavCre^+^ and *Traf6*^−/−^ VavCre^+^ BM cells (n = 6 per group). \*p \< 0.05. Data are represented as mean ± SEM.](nihms966903f1){#F1}

![*Traf6* Deletion Diminishes the Self-Renewal of HSC\
(A) Outline of competitive BM transplantations using VavCre^+^ or *Traf6*^−/−^VavCre^+^ mice.\
(B) Representative flow cytometric analysis of donor-derived (CD45.2^+^) and competitor-derived (CD45.1^+^) PB from recipient mice after competitive transplantation using VavCre^+^ or *Traf6*^−/−^VavCre^+^ BM cells.\
(C) Summary of donor-derived PB proportions at the indicated time points after competitive transplantation using VavCre^+^ or *Traf6*^−/−^VavCre^+^ BM cells (n = 7 per group).\
(D) Proportion of donor-derived VavCre^+^ or *Traf6*^−/−^VavCre^+^ myeloid (CD11b^+^) and lymphoid (CD3^+^ and B220^+^) proportions at the indicated time following competitive transplantation (n = 7 per group).\
(E) Summary of donor-derived BM HSPC proportions at 5 months after competitive transplantation using VavCre^+^ or *Traf6*^−/−^VavCre^+^ BM cells (n = 7 per group).\
\*p \< 0.05. Data are represented as mean ± SEM.](nihms966903f2){#F2}

![Conditional *Traf6* Deletion Diminishes the Long-Term Self-Renewal of HSC\
(A) Outline of competitive BM transplantations using Mx1Cre^+^ or *Traf6*^f/f^Mx1Cre^+^ mice. Briefly, BM cells from Mx1Cre^+^ or *Traf6*^flox/flox^Mx1Cre^+^ mice were mixed at 1:1 ratio with the competitor BM cells, followed by transplantation into lethally irradiated BoyJ mice. One month post-transplantation, pIpC was injected into the recipient mice to induce deletion of *Traf6* (*Traf6*^−/−^Mx1Cre^+^).\
(B and C) Summary of donor-derived PB (B) or BM (C) proportions at 5 months after pIpC injection in primary recipient mice using Mx1Cre^+^ or *Traf6*^f/f^Mx1Cre^+^BM cells (n = 5--7 per group).\
(D) Summary of donor-derived PB proportions at the indicated time points after pIpC injection following primary and secondary competitive transplantations using Mx1Cre^+^ or *Traf6*^−/−^Mx1Cre^+^ BM cells (n = 6 per group).\
(E) Summary of donor-derived BM HSPC proportions at 5 months after secondary competitive transplantation using Mx1Cre^+^ or *Traf6*^−/−^Mx1Cre^+^ BM cells (n = 3 per group). \*p \< 0.05. Data are represented as mean ± SEM.](nihms966903f3){#F3}

![Traf6 Is Required for Maintaining HSC Quiescence\
(A) TUNEL positive VavCre^+^ or *Traf6*^−/−^VavCre^+^ Lin- and Lin+ BM cells (n = 4 per group).\
(B) Representative cell-cycle analysis of VavCre^+^ or *Traf6*^−/−^VavCre^+^ CD150^+^LSK cells.\
(C) Proportion of VavCre^+^ or *Traf6*^−/−^VavCre^+^ CD150^+^LSK cells (left) or LSK cells (right) in G0, G1 and S/G2/M phase (n = 4 per group).\
(D) Frequency of BrdU^+^ staining in VavCre^+^ or *Traf6*^−/−^VavCre^+^ CD150^+^LSK cells (left) or LSK cells (n = 4 per group). \*p \< 0.05. Data are represented as mean ± SEM.](nihms966903f4){#F4}

![Altered Transcriptome in Traf6-Deficient HSPC\
(A) Heatmap of all differentially expressed genes in VavCre^+^ and *Traf6*^−/−^VavCre^+^ LSK cells (1.5-fold; p \< 0.05; n = 4 per group).\
(B) Rank order of enriched gene signatures in VavCre^+^ or *Traf6*^−/−^VavCre^+^ LSK cells based on false discovery rate (FDR) q value (n = 4 per group).\
(C) Gene Set Enrichment Analysis (GSEA) plot enriched in the VavCre^+^ LSK relative to *Traf6*^−/−^VavCre^+^ LSK (top). GSEA plot enriched in *Traf6*^−/−^VavCre^+^ LSK relative to VavCre^+^ LSK (bottom).\
(D) Heatmap generated from the GSEA leading edge genes in VavCre^+^ or *Traf6*^−/−^VavCre^+^ LSK cells.\
(E) Pathway analysis of differentially expressed genes in *Traf6*^−/−^VavCre^+^ LSK relative to VavCre^+^ LSK.](nihms966903f5){#F5}

![Reduced NF-κB Signaling and IKKβ Deficiency Leads to Loss of HSPC and Impaired Hematopoietic Reconstitution\
(A) Expression of NF-κB target genes in VavCre^+^ and *Traf6*^−/−^VavCre^+^ LSK cells as determined by RNA-seq.\
(B) Expression of select NF-κB target genes measured by qRT-PCR in *Traf6*^−/−^VavCre^+^ relative to VavCre^+^ LSK cells.\
(C) Immunoblot analysis of phosphorylated IKKβ, IKKα, and p65 in VavCre^+^ and *Traf6*^−/−^VavCre^+^ Lin^−^ BM cells. Shown below is the relative expression of the indicated proteins calculated by measuring densitometry of the immunoblots.\
(D) Expression and localization of p65 (green) in VavCre^+^ and *Traf6*^−/−^VavCre^+^ LSK cells as determined by indirect immunofluorescence (IF). Shown are representative images from 3 pooled mice per group.\
(E) Outline of competitive BM transplantations using IKK^f/f^VavCre^−^ or IKK^−/−^VavCre^+^ mice.\
(F) Summary of donor-derived PB proportions at the indicated time points after competitive transplantation using IKK^f/f^VavCre^−^ or IKK^−/−^VavCre^+^ BM cells (n = 5 per group). Two independent experiments were performed.\
(G) Representative flow cytometric analysis of donor-derived (CD45.2^+^) and competitor-derived (CD45.1^+^) BM and spleen cells from recipient mice after competitive transplantation using *IKK*^f/f^VavCre^−^ or *IKK*^−/−^VavCre^+^ BM cells.\
(H) Proportion of donor-derived *IKK*^f/f^VavCre^−^ or *IKK*^−/−^VavCre^+^ BM and spleen cells 8 weeks after competitive BM transplantation (n = 5 per group).\
(I) Representative flow cytometric analysis of donor-derived (CD45.2^+^) and competitor-derived (CD45.1^+^) BM LSK cells from recipient mice after competitive transplantation using *IKK*^f/f^VavCre^−^ or *IKK*^−/−^VavCre^+^ BM cells.\
(J) Proportion of donor-derived *IKK*^f/f^VavCre^−^ or *IKK*^−/−^VavCre^+^ LSK BM 8 weeks after competitive BM transplantation (n = 5 per group). \*p \< 0.05. Data are represented as mean ± SEM.](nihms966903f6){#F6}

![Model of Inflammatory and Tonic NF-κB Signaling via TRAF6 during Hematopoietic Stem and Progenitor Cell Homeostasis\
During inflammation, IL-1R, TLRs, and/or TNFRs signaling via TRAF6 results in maximal NF-κB activation in HSPC. In the absence of inflammatory signaling, tonic signals and/or stochastic activation of TRAF6 results in basal NF-κB stimulation required for HSPC homeostasis, including preserving quiescence, self-renewal, and balanced myeloid (My) and lymphoid (Ly) differentiation. In the absence of TRAF6, basal NF-κB activation is diminished, which results in loss of HSPC quiescence and self-renewal.](nihms966903f7){#F7}

###### Highlights

-   TRAF6 is required for hematopoietic stem cell (HSC) homeostasis

-   TRAF6 regulates HSC quiescence, self-renewal, and differentiation

-   Deletion of TRAF6 results in loss of HSC fitness

-   TRAF6 maintains a minimal threshold level of IKKβ/NF-κB signaling in HSC
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